brexucabtagene autoleucel治疗伴中枢神经系统受累的复发/难治性急性淋巴细胞白血病患者的结局
这项回顾性多中心分析利用ROCCA联盟数据,评估brexu-cel在伴中枢神经系统受累的复发/难治性B细胞急性淋巴细胞白血病患者中的安全性和疗效。189例输注患者中31例在采集前有CNS-2或CNS-3病变,中位年龄46.5岁,87.1%接受桥接治疗。再分期可评估的24例中21例(87.5%)达到CNS-1,30例可评估患者中28例达骨髓完全缓解,其中25例可测量残留病阴性;伴与不伴CNS受累者的无进展生存和总生存无统计学显著差异,3/4级免疫效应细胞相关神经毒性综合征发生率分别为35.5%和30%。
要点
- 31例采集前有CNS-2或CNS-3病变的R/R B-ALL患者接受brexu-cel,中位年龄46.5岁,87.1%接受桥接治疗。
- 再分期可评估的24例中21例(87.5%)达到CNS-1,30例可评估患者中28例达骨髓完全缓解、25例可测量残留病阴性。
- 伴与不伴CNS受累者的无进展生存和总生存无统计学显著差异,3/4级ICANS发生率35.5%对30%。
核心结论
- 作者认为,brexu-cel在伴中枢神经系统受累的B-ALL患者中产生高缓解率,毒性可比不伴中枢神经系统受累的患者。
研究设计与样本
- 回顾性多中心分析,使用ROCCA(Real-World Outcomes Collaborative for CAR T in ALL)联盟数据。
- 189例接受brexu-cel输注的患者中,31例在采集前有CNS-2或CNS-3病变,为本报告重点。
- CNS-2定义为脑脊液中出现原始细胞且白细胞<5个/μL,CNS-3定义为出现原始细胞且白细胞>5个/μL和/或临床体征/症状。
主要发现
- 中位年龄46.5岁(范围24-76岁),58.1%为男性,87.1%接受桥接治疗。
- brexu-cel后,24例可进行CNS再分期评估的患者中21例(87.5%)达到CNS-1。
- 30例可评估患者中28例达到骨髓完全缓解,其中25例可测量残留病阴性。
- 伴与不伴CNS受累者的无进展生存或总生存无统计学显著差异。
- 3/4级免疫效应细胞相关神经毒性综合征在伴CNS病变者中发生率为35.5%,在不伴CNS病变者中为30%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor (CAR) T-cell clinical trials. The efficacy and safety of brexucabtagene autoleucel (brexu-cel) in adults with R/R B-ALL was established by the ZUMA-3 trial, which excluded patients with advanced or symptomatic CNS involvement. In this retrospective multicenter analysis, we investigated the safety and efficacy of brexu-cel in patients with CNS B-ALL using data from the ROCCA (Real-World Outcomes Collaborative for CAR T in ALL) consortium. Of 189 patients who received infusion, 31 had CNS-2 (presence of blasts in cerebrospinal fluid with <5 white blood cells [WBCs] per μL) or CNS-3 (presence of blasts with >5 WBCs per μL and/or clinical signs/symptoms) disease before apheresis and are the focus of this report. The median age was 46.5 years (range, 24-76), and 58.1% were male. Most (87.1%) received bridging therapy. After brexu-cel, 21 of 24 patients with CNS restaging (87.5%) achieved CNS-1. Additionally, 28 of 30 evaluable patients achieved marrow complete remission; 25 were measurable residual disease negative. No statistically significant differences were seen in progression-free survival or overall survival after brexu-cel among patients with or without CNS involvement. Similarly, grade 3/4 immune effector cell-associated neurotoxicity syndrome occurred similarly in patients with (35.5%) and without (30%) CNS disease. In conclusion, our data suggest that brexu-cel results in high response rates in patients with CNS B-ALL, with toxicity comparable with that in patients without CNS involvement.
引用
- Muhsen IN, Roloff GW, Faramand R, et al. Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025. PMID: 40334068. doi:10.1182/bloodadvances.2024015779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。